Related Experiment Video
Updated: Aug 16, 2025

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
Published on: September 20, 2020
Identifying optimal candidates for post-TIPS patients with HCC undergoing TACE: a multicenter observational study
Wenzhe Fan1, Bowen Zhu1, Shufan Yue2
1Department of Interventional Oncology, The First Affiliated Hospital of Sun Yat-sen University, 58 Zhongshan 2nd Road, Guangzhou, 510080, People's Republic of China.
A new VACEA score accurately predicts survival for hepatocellular carcinoma (HCC) patients beyond Milan criteria after transjugular intrahepatic portosystemic shunt (TIPS) and transarterial chemoembolization (TACE). This model stratifies patients into risk groups, aiding treatment decisions.
Area of Science:
- Hepatobiliary surgery
- Interventional radiology
- Oncology
Background:
- Hepatocellular carcinoma (HCC) patients beyond Milan criteria often require advanced treatments like transjugular intrahepatic portosystemic shunt (TIPS) followed by transarterial chemoembolization (TACE).
- Accurate prognostic models are crucial for managing these complex cases and guiding treatment selection.
Purpose of the Study:
- To develop and validate a novel prognostic model for patients with HCC beyond the Milan criteria who have undergone TACE after TIPS.
- To compare the performance of the new model against existing prognostic tools.
Main Methods:
- Retrospective analysis of 512 patients from 15 centers (2013-2020) with HCC beyond Milan criteria treated with TACE post-TIPS.
- Development of a prognostic model using multivariate Cox regression, incorporating factors like vascular invasion, AFP, creatinine, extrahepatic spread, and ALT.
- Stratification into risk groups and comparison of predictive performance (AUROC, C-index) with existing models.
Main Results:
- The VACEA score, incorporating vascular invasion, AFP, creatinine, extrahepatic spread, and ALT, significantly stratified patients into four risk groups with distinct survival outcomes.
- The VACEA model demonstrated superior predictive accuracy and discrimination compared to seven other established prognostic models in both training and validation sets.
- Median overall survival ranged from 25.2 months (lowest risk) to 6.2 months (highest risk).
Conclusions:
- The VACEA score provides accurate individual-level prognosis for post-TIPS TACE-treated HCC patients beyond Milan criteria.
- This model effectively stratifies patients into distinct risk categories, aiding in the identification of candidates who may benefit most from this treatment strategy.
- The VACEA score offers improved prognostic discrimination over current TACE/TIPS-specific models.
More Related Videos
09:49Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
Published on: December 2, 2013
12:24A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021